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Abstract
Background: Patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome have a high
risk of progression to end-stage renal disease. The Ponticelli protocol (steroids with alkylating agents) is the most
effective immunosuppressive therapy for this condition, but it has severe adverse effects. Tacrolimus and rituximab
have demonstrated efficacy for remission of nephrotic syndrome in MN with a safer profile. However, the published
evidence is largely based on small or short-term observational studies, historical cohorts, comparisons with conservative
therapy or clinical trials without appropriate control groups, and there is no head-to-head comparison with the Ponticelli
protocol.
Methods: The STARMEN randomized clinical trial will compare the efficacy of sequential tacrolimus–rituximab therapy with a
modified Ponticelli protocol (steroids plus cyclophosphamide). The trial will also evaluate the role of antibodies against the M-
typephospholipaseA2 receptor (anti-PLA2R) and otherantibodies asmarkers of response to treatment and long-termprognosis.
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Results: The trial has already started with 23 patients having been enrolled as of 1 April 2015, an estimated 21.7% of the
estimated sample.
Key words: biomarker, immunosuppression, membranous nephropathy, nephrotic syndrome, randomized controlled trial
Introduction
Primary membranous nephropathy (MN) is the commonest
cause of primary nephrotic syndrome in adults [1]. Up to 30–
50% of high-risk patients will progress to end-stage renal disease
(ESRD) within 5–10 years [2–6]. Antibodies against the M-type
phospholipase A2 receptor (anti-PLA2R) are present in >70% of
cases andhave a pathogenic role [7–9]. The reduction in serum le-
vels of anti-PLA2R during and after therapy could be an early
marker of response to therapy and of sustained remission at
long-term follow-up [10].
Kidney Disease: Improving Global Outcomes guidelines rec-
ommend cyclical treatment with corticosteroids and alkylating
agents (cyclophosphamide or chlorambucil, the ‘Ponticelli proto-
col’) for 6 months for patients with persistent nephrotic syn-
drome after 6–12 months of conservative therapy or with a
decreased baseline renal function [11]. This recommendation is
based on a higher efficacy than supportive therapy to induce re-
missions and to avoid long-term deterioration of renal function
[12–15]. The percentage of remissions after 1 year of treatment
is 50–60%. However, the number and severity of side effects are
important drawbacks of these therapies.
Calcineurin inhibitors (CNI) (cyclosporine or tacrolimus) are
well tolerated and induce a significantly higher number of remis-
sions (70–80% at 1 year) than supportive therapy, especially in
patients with relatively preserved renal function [16–18]. In retro-
spective analyses, cyclosporine was associated with higher
remission rates (85 versus 55%) but also with higher relapse
rates (41 versus 29%) than cytotoxic drugs [17]. Thus, the main
limitation of CNI in MN is the high relapse rate after CNI dis-
continuation (up to 50–60% of patients). In a recent multicentre
Spanish cohort study, monotherapy with tacrolimus induced
remission of nephrotic syndrome in >80% of patients with MN,
with fewadverse events [19]. Thus, in MNpatients with relatively
preserved renal function, tacrolimus may be a therapeutic alter-
native that provides a high remission rate without severe side
effects. However, the frequency of partial versus complete
remission could indicate a higher risk of relapse after tacrolimus
withdrawal. An extended treatment with CNI could be a logical
alternative but may be associated with higher risk of
nephrotoxicity.
Very few studies have directly compared CNI with
corticosteroids–alkylating agents in the treatment of MN. AChin-
ese randomized controlled trial (RCT) showed a significantly
higher remission rate at 6 months among patients treated with
tacrolimus comparedwith cyclophosphamide [20]. A recentmul-
ticentre study from the UK showed that patients treatedwith cor-
ticosteroids and chlorambucil had better renal outcomes than
patients treated with corticosteroids plus cyclosporine, or sup-
portive therapy [21]. However, these patients had a reduced and
declining renal function, a condition where CNI-associated
nephrotoxicity is more relevant.
Rituximab is a monoclonal antibody that depletes CD20+ B
cells and is used in autoimmune diseases and B cell neoplasia
[22]. Several non-controlled studies have reported that rituximab
induces complete remission in 15–20% of primary MN patients
and partial remission in 35–40% [23–25]. Variable doses of rituxi-
mab and different baseline prognostic factors could explain in
part the variability in results [26]. Optimal dose and frequency
and long-term adverse events of rituximab are issues that need
to be better established. Furthermore, a prospective RCT compar-
ing rituximab with supportive treatment or with the Ponticelli
protocol is not available. Rituximabhas also been reported to pre-
vent nephrotic syndrome relapse after CNI withdrawal in a series
of primary MN patients who had a good response to CNI but ex-
hibited a clear CNI dependence thereafter [27]. The efficacy of ri-
tuximab may be compromised by the severity of proteinuria that
may result in urinary losses of rituximab [28] and by the
development of anti-rituximab antibodies following repeated
infusions [29]. In this regard, previous treatment with CNI may
be hypothesized to result in enhanced efficacy of rituximab
by reducing urinary losses and the need for multiple rituxi-
mab courses. Recent observational studies using sequential
tacrolimus–rituximab therapy have supported this hypothesis
by showing a high number of remissions and a low rate of
relapses, with good tolerance [27]. However, no RCT has com-
pared sequential tacrolimus–rituximab with the Ponticelli pro-
tocol recommended by KDIGO guidelines.
Based on this unmet need, the STARMEN RCT (available at
http://www.clinicaltrials.gov, NCT01955187) will compare the
efficacy and safety of sequential treatment with tacrolimus–
rituximab versus steroids plus cyclophosphamide in nephrotic
patients with primary MN [30]. The key outcomes will be remis-
sion of nephrotic syndrome, long-term renal survival and safety.
The STARMEN study will be the first head-to-head trial compar-
ing the Ponticelli protocol with newer therapeutic agents andwill
provide high-quality clinical evidence levels on which to base
recommendations regarding the relative roles of sequential
tacrolimus–rituximab and conventional immune suppression
in the treatment of primary MN.
STARMEN will also address the role of anti-PLA2R antibodies
in the early assessment of the response to therapy using different
therapeutic regimens. Most studies have shown a good correl-
ation between activity of disease and levels of anti-PLA2R [7–10,
31]. In a recent retrospective cohort, the disappearance of anti-
PLA2R during immunosuppressive treatment predicted good
long-term outcome, but persistent detection of anti-PLA2R was
associated with a low probability of persistent remission during
follow-up [31]. These studies suggest that antibody-guided im-
munotherapy may help to personalize the therapeutic regimen.
However, given the use of different techniques for determination
of anti-PLA2R levels and the retrospective design of published
studies, firm conclusions cannot be drawn about the role of
anti-PLA2R as an early biomarker of response to therapy and of
long-term prognosis. An RCT will provide high-quality evidence
on the role of anti-PLA2R to guide therapy and to establish a
prognosis. Novel autoantibodies have been recently described
in patients with primary MN. Circulating antibodies directed
against podocyte cytoplasmic antigens (aldose reductase,
SOD2, α-enolase) or against thrombospondin type-1 domain-
containing 7A could define subsets of patients with positive
anti-PLA2R or persistently negative anti-PLA2R, respectively,
and perhaps with a different response to therapy [32, 33]. These
autoantibodies and their clinical long-term relevance may also
be prospectively validated in this RCT.
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Objectives of the study
Wewill prospectively evaluate the long-term efficacy and safety of
sequential tacrolimus–rituximab therapy compared with steroids–
cyclophosphamide therapy in patients with primary MN.
The principal objective is to evaluate at 24 months whether se-
quential therapy with tacrolimus–rituximab is superior to cyclic-
al treatment (corticosteroids and cyclophosphamide) to achieve
a complete or partial remission with stable renal function.
The secondary objectives are to evaluate the following:
(i) The percentage of patients that achieve a complete and
partial remission with stable renal function at 12 and 18
months.
(ii) The number and time to nephrotic syndrome relapses at
12, 18 and 24 months.
(iii) The time to remission.
(iv) The percentage of patients with preserved renal function
[estimated glomerular filtration rate (eGFR) ≥45 mL/min/
1.73 m2] at 12, 18 and 24 months.
(v) The number of patients with limited response at 12, 18 and
24 months.
(vi) The number of patients with ≥50% increase of serum cre-
atinine (SCr) from baseline at the end of the follow-up.
(vii) The number and severity of side effects during the study.
(viii) Serum anti-PLA2R levels at 6, 12 and 24 months post-
treatment compared with baseline. Optionally, anti-
PLA2R can be obtained at 3, 9 and 18 months.
(ix) The number of immune cells (CD4+ and CD8 + T cells and
CD19+ B cells) after 12 and 24 months of treatment com-
pared with baseline.
An additional aim is to characterize known and novel clinical, la-
boratory and histologic factors that predict response to treat-
ment, relapse and renal outcomes.
Materials and methods
Study design
This is an open label, randomized and active controlled trial
(Phase III study) with three stages: screening and recruitment
of patients, treatment period (6 months for corticosteroids
and cyclophosphamide group, and 9 months for tacrolimus–
rituximab) and a post-treatment follow-up period of 24 months
from initial treatment.
Population
Patients with biopsy-proven idiopathic or primary MN with
nephrotic proteinuria and normal or slightly decreased renal
function will be enrolled.
Inclusion criteria
(i) Patients older than 18 years that provide written informed
consent.
(ii) Biopsy-proven primary MN within 2 years of enrolment. Pa-
tients with nephrotic syndrome relapse after remission (ei-
ther spontaneous or induced by immunosuppression) can
be included without a new renal biopsy if they meet all the
other inclusion/exclusion criteria.
(iii) Estimated GFR ≥45 mL/min/1.73 m2 in at least two measure-
ments performedwithin the 2weeks prior to randomization.
(iv) Nephrotic-range proteinuria (>4 g/day and remaining >50%
of the baseline value) plus hypoalbuminemia (<3 g/dL) dur-
ing at least a 3-month period before screening. These values
must bemet in at least twomeasurements performedwithin
the 2 weeks prior to randomization. Patients showing severe
or disabling symptoms related to the nephrotic syndrome or
severe hypoalbuminemia (<2 g/dL) can be included before
the completion of this 6-month observation period, at the in-
vestigator’s discretion.
(v) Treatment with an angiotensin-converting enzime inhibitor
(ACEI) or angiotensin-receptor blocker (ARB) for at least 2
months before screening [unless intolerance to ACEI/ARB,
contraindications to their use or a low blood pressure (BP)
that could induce side effects, at the investigator’s discre-
tion] with a controlled BP for at least last 3 months (target
<140/90 mmHg).
(vi) Negative urine pregnancy test for potentially fertile females.
Exclusion criteria
(i) Diagnosis of secondary causes of MN: diagnosis of Type 1
or 2 diabetes mellitus, cancer, systemic infections, sys-
temic autoimmune diseases (e.g. systemic lupus erythe-
matosus), amyloidosis, or any other acute or chronic
inflammatory disease.
(ii) Moderate or severe liver disease [aspartate amino-transfer-
ase (AST) and alanine amino-transferase (ALT) >2.5× upper
range limit and total bilirubin >1.5× upper range limit].
(iii) Patientswhoare takingpart inanyother investigational study
and/or are receiving or have received treatment with another
investigational drug or intervention (within 1 month prior to
the study).
(iv) Suspected or known hypersensitivity, allergy and/or im-
munogenic reaction history of any interventional drug or
any of their ingredients (including excipients).
(v) Previous treatment with corticosteroids or any other
immunosuppressive agent in the 6-month period before
screening.
(vi) Previous treatment with rituximab or any other biological
agent in the 2-year period before screening.
(vii) Patients who were non-responders to previous immuno-
suppressant drugs.
(viii) Women showing a positive pregnancy test or during lacta-
tion period or plans to become pregnant.
(ix) Inability or unwillingness of individual or legal guardian/
representative to give written informed consent.
(x) Any other medical unstable, uncontrolled or severe condi-
tion or any other relevant laboratory test finding which, at
the investigator’s own discretion, could increase the asso-
ciated risk of the patient’s participation in the study.
(xi) Current drug or alcohol use or dependence that would
interfere with adherence to study requirements.
Subject withdrawal criteria
The investigator may withdraw a patient from the study at any
time if the investigator considers it necessary for any reason, in-
cluding the following:
(i) Ineligibility (arising either during the study or retrospect-
ively having been overlooked at screening).
(ii) Significant protocol deviation or violation.
(iii) Significant non-compliance or non-adherence with treat-
ment regimen or study requirements.
(iv) An adverse event, especially when serious that requires
discontinuation of the study medication or results in in-
ability to continue to comply with study procedures.
(v) Any medical condition or disease progression, that re-
quires discontinuation of the study medication or results
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in inability to continue to comply with study procedures.
These patients will be followed to analyse whether they
reach end points.
(vi) Consent withdrawn. Patient’s request to withdraw study at
any time.
(vii) Pregnancy.
(viii) Lost to follow-up.
All subjects withdrawn from the studywill be attempted to be in-
cluded in the end-of-treatment visit in order to determine all ef-
ficacy and safety measurements and the patient outcome.
Definitions of end points
Primary end point: The proportion of patients reaching either com-
plete or partial remission at 24 months of study treatment.
Secondary end points:
(i) The number of patients with an increase of SCr ≥50% at the
end of follow-up (renal survival).
(ii) The proportion of patients with relapsing nephrotic syn-
drome among patients who previously underwent partial
remission or complete remission.
(iii) The time to nephrotic syndrome relapse.
(iv) The number of patients with limited response at 12, 18 and
24 months of study treatment.
(v) The percentage of patients with preserved renal function
(eGFR ≥45 mL/min/1.73 m2) at the end of follow-up.
(vi) Serum anti-PLA2R levels before treatment and at 12 and
24 months post-therapy.
(vii) The number of immune cells (CD4+ and CD8+ T cells, and
CD19+ B cells) before treatment and at 12 and 24 months
post-therapy.
(viii) Proportion of patients with drug-related adverse events
during the study.
Figure 1 andTable 1 showa schematic diagramof the trial design,
procedures, stages and data collection, and all trial periods.
Definitions of outcomes
(i) Complete remission: A reduction of proteinuria to ≤0.3 g/24 h
plus stable renal function (eGFR≥45 mL/min/1.73 m2).
(ii) Partial remission: A reduction of proteinuria to 0.3–3.5 g/24 h
and 50% lower than baseline with stable renal function
(eGFR ≥45 mL/min/1.73 m2).
(iii) Limited response: Proteinuria is reduced from baseline level
>50% but remains >3.5 g/24 h.
(iv) Non-response: A reduction of proteinuria <50% from baseline
level.
(v) Renal survival: At the end of the follow-up, sCr does not in-
crease ≥50% of baseline SCr concentrations.
(vi) Relapse: Reappearance of proteinuria >3.5 g/24 h and at
least 50% higher than the lowest post-treatment value in
at least three consecutive visits in those who previously
presented a partial or complete remission.
(vii) Renal function: Thiswill be evaluated bymeans of SCr values
and eGFR, calculated by theModifications inDiet and Renal
Disease four-variable equation (MDRD-4).
Fig. 1. Schematic overview of the STARMEN study. CYC, cyclophosphamide; TAC, tacrolimus; RTX, rituximab.
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Any patient reaching a complete remission or partial remission
will be considered a successful treatment.
Randomization
This studywill be randomized, with an equal allocation ratio (1:1)
to intervention with tacrolimus–rituximab or steroids plus cyclo-
phosphamide. We will use a random number-producing algo-
rithm by central computer systems for simple randomization.
Subject numbers will be assigned sequentially as each subject
enters the study.
Study procedures and baseline determinations
In each centre, potential patients will be identified fromNephrol-
ogy Departments or renal biopsy records. If these patients meet
the selection criteria, they will be proposed to participate in
this trial after giving complete information about their disease,
options of treatment, potential outcomes, risk and benefits of
several therapies, and trial process, including the number of vis-
its, clinical and laboratory determinations, and time of follow-up.
Maximum duration allowed between screening and randomiza-
tion will be 18 months.
The following screening procedures will be recorded in elec-
tronic Case Report Form (eCRF):
Demographics (date of birth, gender, race, smoking and drink-
ing habits, and type of anticonception when applicable)
Medical history (any history of disease or surgical interventions)
Concomitant medication (all over-the-counter or prescription
medication, vitamins and/or herbal supplements)
Physical examination (height, weight, oral temperature, resting
pulse, BP and respiratory rate measurements will be measured
after the participant has sat for at least 5 min)
Electrocardiogram
Laboratory tests (obligatory at baseline in all potential partici-
pants, Table 1).
Blood tests: Red blood cell count, haemoglobin, haematocrit,
white blood cell, platelet count, prothrombin time, activated
partial thromboplastin time, International Normalized ratio,
fibrinogen, glucose, urea, creatinine, uric acid, ALT, AST,
gamma-glutamyl-transpeptidase, partial and total bilirubin, al-
kaline phosphatase, total proteins, albumin, calcium, phos-
phorus, sodium, potassium, total cholesterol, high density
lipoprotein-cholesterol, low density lipoprotein-cholesterol, tri-
glycerides, thyroid-stimulating hormone, intact parathyroid
hormone, 25-hydroxy-vitamin D and beta-human chorionic
gonadotropin in case of doubt of urine pregnancy test.
Urine tests: Sediment, proteinuria in 24 h, creatinine in 24 h,
volume in 24 h and pregnancy test when appropriate.
The following special analyses will be determined at baseline
in all selected participants: serum anti-PLA2R antibodies (ELISA,
Euroimmun AG, Luebeck, Germany), the number of T cells CD4+,
CD8+, CD4+/CD8+ cell ratio, and CD19+ cells. Each participating
centre will collect blood samples for these determinations at
Table 1. Scheme of the activities that will take place at each contact with the participant after randomization
Activity
Months since randomization
0 1 3 6 7 8 9 10 12 15 18 21 24
Study procedures
Informed consent X
Medical history X
Demography data X
Physical examination X X X X X X X X X X
Intervention
Steroids + CF X X X
Tacrolimus + RTX X
a
X X
b
X
b
X
b
X
b
X X X
Blood tests
Haematology X X X X X X X X X X X X X
Biochemistry X X X X X X X X X X X X X
Hormones X X X
Immunology (CD8+, CD4+, CD19+ cells) X Xc X Xc X Xc X
Anti-PLA2R antibodies X X
c X Xc X Xc X
Sample for biobank X X X X
Urine test
Sediment and labstix X X X X X X X
Proteinuria 24 h X X X X X X X X X X X X X
UACR/UPCR X X X X X X X X X X X X X
Sample for biobank X X X X
Evaluation
Complete/partial remission X X X X X X X
Limited/no response X X X X X X X
Renal survival X X X X X X
Relapse X X X X X X
Adverse events X X X X X X X X X X X X
CF, cyclophosphamide; RTX, rituximab; UACR, urinary albumin–creatinine ratio; UPCR, urinary proteinuria–creatinine ratio.
aStart of treatment with tacrolimus at initial dosages of 0.05 mg/kg/day based on serum drug concentrations of 5–7 ng/mL.
bStart of treatment with rituximab: cycle of 1 g IV (single dose) and decrease tacrolimus dosages at 25% per month, starting at the end of Month 6, resulting in a complete
withdrawal at the end of Month 9.
cThese determinations will be optional (Months 3, 9 and 18).
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Months 0, 6, 12 and 24, and optionally atMonths 3, 9 and 18. Blood
samples for these special determinations shall be kept in each
participating centre at −80°C. These samples will be sent to and
processed in the Research Laboratory of Renal and Vascular Path-
ology, of the Nephrology Department at the Hospital Universitar-
io Fundación Jiménez Díaz (Dr Jesus Egido), in Madrid (Spain).
Subsequent assessments
For each visit, we will check eligibility, end points/outcome mea-
sures, safety (general and specific safety assessments, e.g. specif-
ic laboratory tests), adverse event collection, dispensing of study
drugs, compliance with study drugs, recording of concomitant
medications, and laboratory tests to evaluate treatment response
as defined in the schedule.
End of trial assessment
The end of trial will be the date of the last scheduled visit of the
last participant.
The end of study visit form should include assessment of end
points/outcome measures, general and specific safety assess-
ments (e.g. specific laboratory tests), adverse event collection, as-
sessment of compliance with study drugs and recording of
concomitant medications.
Treatment protocol
First Arm: Cyclical corticosteroids/cyclophosphamide for 6
months.
Months 1, 3 and 5: 1 g IVmethylprednisolone daily (Days 1–3),
then oral methylprednisolone (0.5 mg/kg/day) for 27 days (Days
4–30).
Months 2, 4 and 6: Oral cyclophosphamide (2.0 mg/kg/day) for
30 days.
Second Arm: Sequential tacrolimus–rituximab
(i) Tacrolimus: Initial dose of 0.05 mg/kg/day oral, adjusted to
achieve blood trough levels of 5–7 ng/mL for 6months. Start-
ing at the end of Month 6, tacrolimus dosagewill be reduced
by 25% permonth, resulting in a completewithdrawal at the
end of Month 9.
(ii) Rituximab: A single dose of 1 g IV will be given at Day 180,
before the onset of tacrolimus dose reduction.
In active control patients showing a 50% SCr increase, possible
confounding factors such as an excessive diuretic doses or non-
renal volume loss will be carefully excluded before adjudicating
an end point.
In the tacrolimus arm, tacrolimus doses will be reduced by
25% every 2 weeks in the presence of a 50% SCr increase. If the
elevated SCr persists at >50% of baseline values 2–4 weeks after
>75% reduction of tacrolimus doses, an end point will be adjudi-
cated. Once the end point of a 50% increase in baseline SCr con-
centrations has been established in either group, the patient will
be taken off the study and hewill be treated according to the best
local practice.
To minimize infusion reactions with rituximab, patients will
receive premedication with methylprednisolone 100 mg intra-
venously. Other additional drugs will be permitted according to
each country’s usual protocols, for example, oral acetamino-
phen/paracetamol (1 g) and diphenhydramine hydrochloride
(50 mg).
Both treatment groupswill receive antibiotic prophylaxiswith
cotrimoxazole (trimethoprim/sulfamethoxazole 160/800 mg, or-
ally) three times a week during periods of treatment.
Assessment of efficacy and safety
Variables of efficacy:
(i) The number of patients with complete remission or partial
remission of nephrotic syndrome at 6, 12, 18 and 24 months.
(ii) The number of nephrotic syndrome relapses at 12, 18 and
24 months.
(iii) The number of patients maintaining stable renal function at
6, 12, 18 and 24 months.
(iv) The number of patients reaching ESRD at 6, 12, 18 and 24
months.
Variables of safety:
(i) The number and severity of side effects at 6, 12, 18 and 24
months.
(ii) The number of patients withdrawn from the study because
of side effects or drug intolerance at 6, 12 and 18 months.
Statistical analysis
Datawill be entered by the principal investigator at each centre or
their nominated deputies onto a central secure database. Con-
tinuous variables with normal distribution will be reported as
mean ± SD. Otherwise, they will be reported asmedian and quar-
tiles. Categorical variables will be reported as frequency. Differ-
ences between the two groups in continuous variables will be
analysed using the unpaired Student’s t-test or Wilcoxon’s rank
sum test, as appropriate. Differences between categorical vari-
ables will be analysed with likelihood chi-square and Fisher’s
exact tests, as appropriate. In both groups, for proteinuria, SCr
and eGFR, study of changes since randomization until Months
3, 6, 9, 12, 18 and 24 will be assessed by covariance analysis (AN-
COVA). Differences between treatmentswill be estimated by fixed
model.
Major end points in each arm of treatment will be deter-
mined as the proportion of events at the end of the follow-
up. Primary end point (complete or partial remission) will be
analysed at a one-tailed significance level of P < 0.05. Based
on previous studies, we estimated that complete or partial re-
mission will occur in 60% in the Ponticelli group and 85% in ta-
crolimus–rituximab group, a clinically relevant difference of
25% between experimental groups. Other outcomes will be as-
sessed by a two-tailed significance level of P <0.05. We will de-
termine the probability of outcomes as time-to-event with the
Kaplan–Meier curves, log-rank test and Cox’s regression from
baseline evaluation to last follow-up. Baseline factors asso-
ciated with major outcomes will be determined with propor-
tional hazard Cox’s model. Results will be reported as hazard
ratio with 95% confidence interval. All statistical analyses will
be performed by a statistician who does not know the treat-
ment groups, with Stata version 13.0 for Windows (Stata
Corp., TX, USA).
Handling of missing data, withdrawals and subgroup
analyses
All analyses will be done on an intention-to-treat basis, inde-
pendently of numbers of non-compliers, withdrawals or lost to
follow-up. Additionally, we will do analysis per protocol. Results
will be reported with both analyses [34–37].
In case of a small number of missing data, we will use a
method of multiple imputations using a mixed effects linear
regression method, and we will perform a standard analysis
for each imputation cycle. The final analysis will take into
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consideration the variability across the imputation cycles. Re-
sults will be reported with missing data and with imputation
method.
Based on known prognostic factors, subgroup analyses will be
carried out. These results will be interpreted with caution and
used to refine the primary hypothesis and specify to whom the
intervention should be recommended. However, in general,
these potential results only will be considered as hypothesis-
generating to design new trials.
Sample size calculation
We will consider the proportion of patients with proteinuria
remission (complete or partial) after treatment and at 2 years
of follow-up. On the basis of previous studies, we assumed a
remission of 60% for the steroids + cyclophosphamide group
(p0) and 85% for tacrolimus–rituximab (p1), a difference be-
tween groups of 25%, a statistical power 80% and an alpha
error 0.05 (one-tailed test).
Due to p1 > 0.80 (group of tacrolimus–rituximab), we used the
following formulae with Fleiss’ correction for binary outcomes:
n1 ¼
ðzα=2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiðrþ 1ÞRð1 RÞp þ zβ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p0ð1 p0Þ þ rð p1Þð1 p1Þ
p 2
rð p1  p0Þ2
n0 ¼ r × n1
R ¼ p1 þ rð p0Þ
1þ r
Fleiss correction: n1c ¼ n1þ ðrþ 1Þ=Rð p1  p0Þ
where p0 is the proportion of remission in the control group
(methylprednisolone–cyclophosphamide), p1 is the proportion
of remission in experimental group (tacrolimus–rituximab), n0
is the number of participants in methylprednisolone–cyclophos-
phamide group, n1 is the number of participants in the tacroli-
mus–rituximab group, r is the ratio between groups (n0/n1) and
R is the risk in total population. Values of z-alpha and z-beta,
are respectively, 1.645 and 0.842.
With this method, wewould need 47 patients per group and a
total sample size of 94 patients. Furthermore, we assumed that
10% of patients will be withdrawals. We used the following cor-
rection: N* =N/(1 − R*), where R* is the assumed proportion of
withdrawals patients (in this case, 10% of initial number).
After this correction, we will need 53 patients by group and
106 patients. These results were reproduced with the STATA
command ‘db nsize’ and with command ‘power two proportions’
with correction for continuity. The estimated recruitment period
at each participant centre is 18 months.
Interim analyses and stopping rules
An independent monitoring committee will ensure the safety of
the participants and the integrity of the trial. This committeewill
perform the interim analyses in coordination with data analysts,
suggesting if necessary, additional analysis. The reasons for ter-
minating the trial will be safety or poor study performance (e.g.
slow accrual, high losses to follow-up and poor quality control).
Any evidence that compromises patient safety or any statistical
rule could lead to a temporary suspension of enrollment of
patients or any study intervention until the safety committee
conducts a review of the case.
Current status of the trial
The trial has already started. The first patient was enrolled on 10
June 2014. As of 1 April 2015, 23 patients have been enrolled and
randomized (21.7% of estimated sample).
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